Dr Guy Harmelin has extensive experience in healthcare and technology investment and entrepreneurship. Guy was previously on the leadership team at Harel Insurance Investments and Financial Services, the largest insurance group in Israel with over $71 billion in assets under management. Guy has invested and worked with multiple successful companies including Lemonade, Innoviz, American Well, Ecoppia, Ayala Pharma, Biond Biologics, Tabit, Assured Allies, Quantum Machines, Rafael and Ein-Tal Hospitals.
Prior to joining Harel, Guy was the Co-Founder and CEO of RondinX, a computational drug target discovery Company which merged with BiomX and went public on NYSE in November 2019, PHGE.
Guy has an MD Summa Cum Laude from the University of Florence and served as a Resident Physician at the Tel Aviv Medical Center.
Rona Segev is a founding partner at TLV Partners. TLV Partners is a venture capital firm with $270M under management and is one of the most dominant VCs in the Israeli start-up ecosystem. Rona has invested in and worked with many successful companies, including Varonis (Went Public on Nasdaq in February 2014, VRNS), Skycure (acquired by Symantec), Puresec (Acquired by Palo Alto Networks), Traiana (acquired by ICAP), Worklight (acquired by IBM), Actona (acquired by CISCO), ItemField (acquired by Informatica), Identify (acquired by BMC), Aduva (acquired by SUN), Fring (acquired by GenBend), SalesPredict (acquired by eBay) and Totango.
Ayala Pharmaceuticals, Biond Biologics, Ecoppia, Oxford Nanopore Technologies, and Tabit
Aqua Security, DataGen Technologies, Firebolt, Run:AI, and Unit